Your browser doesn't support javascript.
loading
A national mixed-mode seroprevalence random population-based cohort on SARS-CoV-2 epidemic in France: the socio-epidemiological EpiCov study
Josiane WARSZAWSKI; Nathalie BAJOS; Muriel BARLET; Xavier de LAMBALLERIE; Delphine RAHIB; Nathalie LYDIE; Sylvain DURRLEMAN; Remy SLAMA; Remonie SENG; Philippe RAYNAUD; Aude LEDUC; Guillaume BAGEIN; Nicolas PALIOD; Stephane LEGLEYE; Cyril FAVRE-MARTINOZ; Laura CASTELL; Patrick SILLARD; Laurence Meyer; Francois BECK; - The EPICOV study group.
Afiliação
  • Josiane WARSZAWSKI; Inserm CESP U1018 - UMRS 1018, Université Paris-Saclay - AP-HP, Epidemiology and Public Health Service, Le Kremlin-Bicetre, France
  • Nathalie BAJOS; IRIS, INSERM, EHESS, CNRS Aubervilliers, France
  • Muriel BARLET; DREES - Direction de la Recherche, Etudes, Evaluation et Statistiques, Paris, France
  • Xavier de LAMBALLERIE; Unité des Virus Emergents, UVE, Aix Marseille Univ, IRD 190, INSERM 1207, IHU Mé diterranee Infection, Marseille, France
  • Delphine RAHIB; Santé Publique France, Saint-Maurice France
  • Nathalie LYDIE; Santé Publique France, Saint-Maurice France
  • Sylvain DURRLEMAN; Institut thématique de Santé Publique, INSERM, Paris France
  • Remy SLAMA; Institut thématique de Santé Publique, Inserm, Paris, CNRS, Team of Environmental Epidemiology applied to Reproduction and Respiratory Health, Institute for Adv
  • Remonie SENG; AP-HP Epidemiology and Public Health Service, Paris-Saclay, Le Kremlin-Bicetre, France
  • Philippe RAYNAUD; DREES - Direction de la Recherche, des Etudes, Evaluation et Statistiques, Paris, France
  • Aude LEDUC; DREES - Direction de la Recherche, des Etudes, Evaluation et Statistiques, Paris, France
  • Guillaume BAGEIN; DREES - Direction de la Recherche, des Etudes, Evaluation et Statistiques, Paris, France
  • Nicolas PALIOD; INSEE - Institut National de la Statistique et des Etudes Economiques, Montrouge, France
  • Stephane LEGLEYE; INSEE - Institut National de la Statistique et des Etudes Economiques, Montrouge, and INSERM CESP U1018, Univ Paris-Saclay, Le Kremlin-Bicetre, France
  • Cyril FAVRE-MARTINOZ; INSEE - Institut National de la Statistique et des Etudes Economiques, Montrouge, France
  • Laura CASTELL; INSEE - Institut National de la Statistique et des Etudes Economiques, Montrouge, France
  • Patrick SILLARD; INSEE - Institut National de la Statistique et des Etudes Economiques, Montrouge, France
  • Laurence Meyer; Inserm CESP U1018 - UMRS 1018, Université Paris-Saclay - AP-HP, Epidemiology and Public Health Service, Le Kremlin-Bicetre, France
  • Francois BECK; INSEE - Institut National de la Statistique et des Etudes Economiques, Montrouge, and INSERM CESP U1018, Univ Paris-Saclay, Le Kremlin-Bicetre, France
  • - The EPICOV study group;
Preprint em Inglês | medRxiv | ID: ppmedrxiv-21252316
ABSTRACT
Backgroundthe EpiCov study, initiated at the end of the first national lockdown in France, aimed to provide national and regional estimates of the seroprevalence of SARS-CoV-2 infection, and to analyze relations between living conditions and the dynamics of the epidemic. We present and discuss here the survey methodology, and describe the first-round fieldwork. Method371,000 individuals aged 15 years or more were randomly selected from the national tax register, stratified by departments, including three overseas departments, and by poverty level with over-representation of people living below the poverty line. Health, socio-economics, migration history, and living conditions were collected through self-computed-assisted web interviews or via computer-assisted telephone interviews. The first-round survey was conducted in May. A random subsample was eligible to receive material for home blood self-sample on dried blood spot (DBS), in order to detect IgG antibodies against the spike protein (Euroimmun ELISA-S), and neutralizing antibodies for non-negative ELISA-S. For the second-round conducted in November, all respondents were eligible for the antibodies detection from home DBS sample, as well as the other household members aged 6 years or more for 20% of them. Participation and adjustment for nonresponse134,391 respondents completed the first-round questionnaire from May 2 to June 1, 2020, including 16,970 (12.6%) respondents under the poverty line. Multimodal web/tel interviews was randomly assigned to 20% of the sample. The other were assigned to exclusive CAWI. Overall 17,441 respondents were eligible for home blood sample, among them 12,114 returned the DBS (interquartile date May 25-June 5). The response probability was first estimated from logit models adjusted on a wide range of auxiliary demographic and socio-economic variables available from the sampling frame, and final weights calibrated to the margins of the population census permitted to correct for a large part of the non-response bias. ConclusionThe Epicov study is one of the largest national random population-based seroprevalence cohort, with both an epidemiological and sociological approaches to evaluate the spread of the COVID-19 epidemic, and the impact on health and living conditions. One of the major interests of this study is the broad coverage of the socio-economic and territorial diversity of the population.
Licença
cc_no
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Cohort_studies / Experimental_studies / Estudo observacional / Estudo prognóstico / Pesquisa qualitativa / Rct Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Cohort_studies / Experimental_studies / Estudo observacional / Estudo prognóstico / Pesquisa qualitativa / Rct Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
...